Search results
John was Illumina’s first CEO, and most recently its COO. After leaving Illumina, John co-founded Ariosa (a Venrock portfolio company), serving as its Executive Chairman until its acquisition by Roche. In addition, John was the Chairman at Sequenta until its acquisition by Adaptive (Nasdaq: ADPT).
Location: Santa Barbara · 500+ connections on LinkedIn. View John Stuelpnagel’s profile on LinkedIn, a professional community of 1 billion members.
Mar 6, 2022 · John Stuelpnagel co-founded Illumina in 1998 as its first CEO. Trained as a biochemist, Stuelpnagel started working on CW Group (Larry Bock’s firm) after getting his MBA at UCLA.
As co-founder and the first CEO of Illumina, Dr. Stuelpnagel is a seasoned genomics industry entrepreneur and pioneer with extensive experience building and scaling high-growth companies and commercializing disruptive technologies.
Jan 13, 2015 · John Stuelpnagel – one of Illumina‘s cofounders – has never had his genome sequenced. “I didn’t feel the need,” Stuelpnagel said.
Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area.
John Stuelpnagel has been Chairman of Inscripta since March 2017. He cofounded and was Executive Chairman of Ariosa from 2010 to 2015 when the company was acquired by Roche. He was also the Chairman of Sequenta from 2010 to 2015 when that company was merged with Adaptive Biotechnologies where he continues as a member of the board.
